Industry News
Biotechnology Industry News
As pharmas like Eli Lilly and…
As pharmas like Eli Lilly and Roche bolster their biotech offerings, Pfizer is snuffing out its program designed to incubate new innovations from select companies, dubbed Pfizer Ignite.
Vistagen Therapeutics is doubling…
Vistagen Therapeutics is doubling down on its lead social anxiety candidate, even after the asset failed a phase 3 trial last December. The Bay Area biotech is laying off about 20% of its staff to
An Ultragenyx gene therapy has…
An Ultragenyx gene therapy has scored a win at the midway point of its phase 3 trial, successfully reducing ammonia levels in patients with a rare urea cycle disorder.
Small molecules make up almost…
Small molecules make up almost half of the 20 most valuable orphan drugs in development across biopharma, according to an Evaluate analysis.
BridgeBio Pharma has taken another…
BridgeBio Pharma has taken another step toward the potential approval of its muscle weakness drug candidate BBP-418, reporting statistically significant phase 3 efficacy data that analysts called impressive.
Novo Holdings saw its assets…
Novo Holdings saw its assets shrink by a third last year as part of the fallout of Novo Nordisk’s nosediving share price.
Regenxbio has guided its Duchenne…
Regenxbio has guided its Duchenne muscular dystrophy gene therapy candidate through another test, reporting a clean safety profile and functional improvements as it heads toward pivotal data.
Evotec has escalated its already…
Evotec has escalated its already substantial reorganization, plotting an additional round of layoffs and site closures that will impact one-sixth of the German drug discoverer’s workforce.
With a fresh leadership team…
With a fresh leadership team settling in, CNS Pharmaceuticals is wiping its pipeline clean as it hunts for a new lead asset in a strategic pivot.
French biotech Enodia Therapeutics…
French biotech Enodia Therapeutics is paying $1 million upfront in a back-loaded deal for Kezar Life Sciences’ preclinical protein degradation program.
Salspera has set out plans for a…
Salspera has set out plans for a $91 million IPO to fund the phase 3 study of its bacteria-based cancer therapy.
Less than a week after Roche…
Less than a week after Roche pledged a hefty investment in the South Korean biopharma industry, Eli Lilly is following suit with a $500 million, five-year pact of its own.
Molecular glue-focused biotech f5…
Molecular glue-focused biotech f5 Therapeutics has failed to stick around for the long haul, shuttering after six years, according to an announcement from the company’s CEO on LinkedIn.
The FDA has resumed review of…
The FDA has resumed review of Capricor Therapeutics’ previously rejected Duchenne muscular dystrophy cell therapy following the biotech’s submission of more clinical data.
As tensions around the FDA…
As tensions around the FDA continue to escalate, a Republican U.S. senator has announced an investigation into recent approval rejections for rare disease candidates, according to Bloomberg News.
Voyager Therapeutics has hit pause…
Voyager Therapeutics has hit pause on a preclinical Alzheimer’s disease program just eight months after unveiling the asset.
Ascletis Pharma has posted phase 2…
Ascletis Pharma has posted phase 2 data on its ultra-long-acting GLP-1 receptor analog, generating early evidence that the formulation may support quarterly dosing as a maintenance therapy.
Kalaris Therapeutics has paused a…
Kalaris Therapeutics has paused a phase 1 study of its next-gen eye drug while it attempts to finally resolve cases of eye inflammation.
BioNTech’s CEO and his fellow…
BioNTech’s CEO and his fellow co-founder will depart the mRNA powerhouse by the end of the year to helm a new company focused on “next generation mRNA innovations.”
Vertex reported a phase 3 win for…
Vertex reported a phase 3 win for its kidney disease prospect povetacicept, meeting analyst expectations and firing the starting gun on a race to the FDA that could result in an accelerated approval in November.